-

Electromed, Inc. Appoints Michael J. MacCourt as Chief Financial Officer

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Michael J. MacCourt as the Company’s Chief Financial Officer, effective May 26, 2020.

Mr. MacCourt brings to Electromed approximately two decades of financial leadership and multidimensional business experience across a range of medical device, consulting and Fortune 500 companies. Prior to his most recent role as Senior Director of Commercial Finance at Starkey Hearing Technologies, Mr. MacCourt spent over nine years at Medtronic in roles of increasing responsibility; concluding as Divisional CFO of the Lung Health business for the last five years. Mr. MacCourt also has an extensive consulting background primarily at PricewaterhouseCoopers, where he held management roles in both financial process improvement and business analytics. Mr. MacCourt started his career at Procter & Gamble and then ConAgra Foods, where he held Financial Analyst, Cost Analyst and Business Analyst positions.

Kathleen Skarvan, Electromed’s President and CEO, commented, "On behalf of our Board of Directors and management team, I am delighted to welcome Mike to Electromed. He is a dynamic financial executive with a strong track record of building high-performing teams, solving complex business problems, driving market development and optimizing the finance function through a collaborative leadership style. In Mike, we found an incredible cultural fit. He is a high-energy team player with a keen strategic mind, complemented by top-notch financial and analytical acumen.”

Mr. MacCourt added, "I am thrilled to be joining a company that prioritizes innovation, quality of product and customer service in delivering its SmartVest® airway clearance devices to patients with compromised pulmonary function. I look forward to helping the team drive profitable growth in the years to come.”

Jeremy Brock, Electromed’s current Chief Financial Officer, will remain with the Company in a supporting role through July 1, 2020 to ensure a smooth CFO transition.

About Electromed, Inc.
Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Contacts

Electromed, Inc.
Kathleen Skarvan, President and Chief Executive Officer
(952) 758-9299
investorrelations@electromed.com

The Equity Group Inc.
Kalle Ahl, CFA
(212) 836-9614
kahl@equityny.com

Devin Sullivan
(212) 836-9608
dsullivan@equityny.com

Electromed, Inc.

NYSEAM:ELMD

Release Versions

Contacts

Electromed, Inc.
Kathleen Skarvan, President and Chief Executive Officer
(952) 758-9299
investorrelations@electromed.com

The Equity Group Inc.
Kalle Ahl, CFA
(212) 836-9614
kahl@equityny.com

Devin Sullivan
(212) 836-9608
dsullivan@equityny.com

More News From Electromed, Inc.

Electromed, Inc. to Participate in the Sidoti December Virtual Micro Cap Investor Conference

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Kathleen Skarvan, President and Chief Executive Officer, and Mike MacCourt, Chief Financial Officer, are scheduled to participate in the Sidoti December Virtual Micro Cap Investor Conference on December 8-9, 2021. Management will be available for one-on-ones throughout both days. Below are the details for Electrome...

Electromed, Inc. Announces Fiscal 2022 First Quarter Financial Results

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2021 (“Q1 FY 2022”). Q1 FY 2022 Highlights Net revenue increased 25.0% to $10.0 million, from $8.0 million for the three months ended September 30, 2020 (“Q1 FY 2021”), driven by 24.4% home care revenue growth and 61.5% institutional revenue growth. Gross profit...

Electromed, Inc. Schedules its First Quarter Fiscal 2022 Financial Results Conference Call for November 9, 2021 at 5:00 p.m. ET

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2022 first quarter ended September 30, 2021, on Tuesday, November 9, 2021 after the close of the stock market and host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by d...
Back to Newsroom